StockGlow

Provectus Biopharmaceuticals, Inc. (PVCT)

Develops immunotherapy drugs using rose bengal to treat cancer, infections, and skin diseases.

$0.06-0.04%Healthcare
Compare PVCT with
StockGlow Score
24
Leaning Bearish
BearishBullish
1 year ago-34.9%

The outlook

PVCT is trading near the low end of its 52-week range and sits below both its 50- and 200-day moving averages, signaling weak near-term momentum. Analyst coverage appears limited or absent. The overall sentiment leans bearish based on current technical positioning.

What’s behind the score

Price trendBelow its 50- & 200-day averages
52-week range33% of the way from its 52-week low to high
Market cap
$25.2M
52-wk high
$0.11
52-wk low
$0.04
50-day avg
$0.06
200-day avg
$0.06
Trailing P/E
—

Similar stocks

IMUCEOM Pharmaceuticals Holdings, Inc.$0.24+13.83%NAVBQNavidea Biopharmaceuticals, Inc.$0.00+0.00%NWBONorthwest Biotherapeutics, Inc.$0.17-0.69%TLOGTetraLogic Pharmaceuticals Corporation$0.00+0.00%ACURAcura Pharmaceuticals, Inc.$0.00-66.67%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy